Dr Adam Hargreaves
York-based bio-tech firm the Aptamer Group says since it fundraised £2.6million in July, it has met cost-base reduction targets, streamlined scientific production capabilities, and executed a new commercial growth strategy to deliver optimised products of high quality to a growing customer base.
Non-exec director Dr Adam Hargreaves told last week’s AGM: “Attracting new partners has ensured that we are now working with the majority of the larger global pharmaceutical companies, alongside a wealth of diagnostic, healthcare, and niche biotech partners.
“Particular highlights have included the development of a vertical market platform in fibrosis, in which we are working with AstraZeneca; the progression toward human trials of our deodorant Optimer product with Unilever; and the successful production of an Optimer delivery conjugate to an undisclosed genetic medicines company, with which they are planning pre-clinical trials.”
“Our increased commercial traction has secured newly signed contracts, currently up to the value of £471,000, which will ensure that the Group’s cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period.
The Board looks forward to updating shareholders on further progress in due course.”